Sun Min Lim - JoVE Visualize

Showing results (131-140 of 140) with videos related to

Pageof 14

Sort By:

You have reached the last page of results.This site can display upto 140 results.

Frontiers in Chemistry|December 22, 2022

YH29407 with anti-PD-1 ameliorates anti-tumor effects <i>via</i> increased T cell functionality and antigen presenting machinery in the tumor microenvironmentDong Kwon Kim, Chun-Bong Synn, Seung Min Yang, et al.

Frontiers in Oncology|March 31, 2022

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell ImmunityWongeun Lee, Dong Kwon Kim, Chun-Bong Synn, et al.

Molecular Cancer Therapeutics|December 5, 2024

Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with PembrolizumabDong Kwon Kim, Chun-Bong Synn, Wongeun Lee, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2026

Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 studyBarbara Burtness, Ari J Rosenberg, Benoit Calderon, et al.

Cancer Research and Treatment|May 12, 2018

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell CarcinomaSun Min Lim, Sang Hee Cho, In Gyu Hwang, et al.

Clinical & Translational Immunology|January 10, 2022

SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsChun-Bong Synn, Sung Eun Kim, Hee Kyu Lee, et al.

European Journal of Cancer (Oxford, England : 1990)|July 29, 2025

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.

Journal of Pathology and Translational Medicine|July 19, 2024

Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSPMiso Kim, Hyo Sup Shim, Sheehyun Kim, et al.

Cancer Research and Treatment|December 1, 2023

Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSPMiso Kim, Hyo Sup Shim, Sheehyun Kim, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2024

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 StudyNatasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.

Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:

Pageof 14

You have reached the last page of results.This site can display upto 140 results.

Frontiers in Chemistry|December 22, 2022

YH29407 with anti-PD-1 ameliorates anti-tumor effects <i>via</i> increased T cell functionality and antigen presenting machinery in the tumor microenvironmentDong Kwon Kim, Chun-Bong Synn, Seung Min Yang, et al.

Frontiers in Oncology|March 31, 2022

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell ImmunityWongeun Lee, Dong Kwon Kim, Chun-Bong Synn, et al.

Molecular Cancer Therapeutics|December 5, 2024

Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with PembrolizumabDong Kwon Kim, Chun-Bong Synn, Wongeun Lee, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2026

Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 studyBarbara Burtness, Ari J Rosenberg, Benoit Calderon, et al.

Cancer Research and Treatment|May 12, 2018

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell CarcinomaSun Min Lim, Sang Hee Cho, In Gyu Hwang, et al.

Clinical & Translational Immunology|January 10, 2022

SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer modelsChun-Bong Synn, Sung Eun Kim, Hee Kyu Lee, et al.

European Journal of Cancer (Oxford, England : 1990)|July 29, 2025

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.

Journal of Pathology and Translational Medicine|July 19, 2024

Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSPMiso Kim, Hyo Sup Shim, Sheehyun Kim, et al.

Cancer Research and Treatment|December 1, 2023

Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSPMiso Kim, Hyo Sup Shim, Sheehyun Kim, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2024

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 StudyNatasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.

Pageof 14